CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES >
CRISPR/Cas9-based generation of the bfd2 deficient strain of Toxoplasma gondii and analysis its phenotype
Received date: 2024-12-27
Revised date: 2025-01-31
Online published: 2025-04-24
Supported by
Clinical Research Special Project for Young Scholars in Shanghai Health Commission(20214Y0206);Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2023-2025) Key Discipline Project(GWVI-11.1-12)
Objective To generate the bradyzoite formation deficiency 2 (bfd2) gene-deficient Toxoplasma gondii ME49 strain based on clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 system, analyze the phenotype of the strain, and investigate the effect of bfd2 on T. gondii differentiation and proliferation. Methods Small guide RNA (sgRNA) for bfd2 was designed using the E-CRISPR tool, and the sgRNA in the pSAG1::CAS9-U6::SgUPRT plasmid was mutated using the Q5 Site-Directed Mutagenesis Kit to generate the pSAG1::CAS9-U6::SgBFD2 plasmid. The pyrimethamine resistance gene and the upstream and downstream sequences of the bfd2 gene were ligated to form donor DNA and cloned into the pUC19 plasmid, and donor DNA was amplified using PCR assay. The pSAG1::CAS9-U6::SgBFD2 plasmid and donor DNA fragments were electroporation co-transfected into tachyzoites of the T. gondii ME49 strain. Following electroporation, the suspension was inoculated into human foreskin fibroblasts (HFFs), and the electroporated parasite strains were subjected to monoclonal selection with 3 μmol/L pyrimethamine. The screened monoclonal parasite strains were inoculated into HFF cells and passaged, and the Δbfd2 knockout efficiency in the strain was checked using PCR assay. The proliferation of the strains was measured in HFF cells using in vitro proliferation assays, and the plaque-forming ability of the strain was tested in HFFs using plaque assays. In addition, the pathological changes in livers of mice infected with the strains were observed using hematoxylin and eosin (HE) staining. All statistical analyses were performed using the software GraphPad Prism 9, and the experimental data was tested for statistical significance using two-tailed non-paired Student t-test and analysis of variance (ANOVA). Results The pSAG1::CAS9-U6::SgBFD2 and donor DNA plasmid were successfully generated. The dihydrofolate reductase (DHFR)-coding sequence was successfully inserted to the target site, and the monoclonal ME49 ∆bfd2 gene knockout strain (ME49 ∆bfd2 strain) was successfully screened as verified by PCR assay. In vitro proliferation assays revealed that the proportions of parasitophorous vacuoles containing more than 16, 16 and 8 and less tachyzoites were (55.33 ± 5.03)%, (27.00 ± 3.00)% and (17.67 ± 4.04)% in HFF cells inoculated with the ME49 strain, and (25.33 ± 4.16)%, (42.67 ± 3.06)% and (32.00 ± 6.93)% in HFF cells inoculated with the ME49 ∆bfd2 strain, and the number of parasitophorous vacuoles containing more than 16 tachyzoites was higher in HFF cells infected with the ME49 strain than in cells infected with the ME49 ∆bfd2 strain (t = 6.337, P < 0.01). Plaque assays showed (13.50 ± 3.11), (119.75 ± 4.86) and (264.25 ± 28.61) plaques in HFFs inoculated with 100, 1 000 and 10 000 tachyzoites of the ME49 strain, and (1.25 ± 0.96), (6.75 ± 0.96) and (22.00 ± 5.72) plaques in HFFs inoculated with 100, 1 000 and 10 000 tachyzoites of the ME49 ∆bfd2 strain (t = 7.415, 57.72, 18.04, all P < 0.01). HE staining showed alleviation of liver inflammation in mice infected with the ME49 ∆bfd2 strain relative to in mice infected with the ME49 strain. Conclusion The BFD2 deficient strain of T. gondii has been successfully generated using the CRISPR/Cas9 system, and BFD2 deficiency inhibits T. gondii differentiation and proliferation and alleviates liver inflammation in mice.
ZHANG Xiaocheng , HU Yuan , PENG Hui , SHEN Yujuan , LIU Hua , CAO Jianping . CRISPR/Cas9-based generation of the bfd2 deficient strain of Toxoplasma gondii and analysis its phenotype[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2025 , 43(2) : 217 -222 . DOI: 10.12140/j.issn.1000-7423.2025.02.011
| [1] | Atif I, Touloun O, Boussaa S. Toxoplasma gondii in humans, animals and in the environment in Morocco: A literature review[J]. Gut Pathog, 2024, 16(1):53. |
| [2] | Hussain MA, Stitt V, Szabo EA, et al. Toxoplasma gondii in the food supply[J]. Pathogens, 2017, 6(2): 21. |
| [3] | Sgroi G, Viscardi M, Santoro M, et al. Genotyping of Toxoplasma gondii in wild boar (Sus scrofa) in southern Italy: Epidemiological survey and associated risk for consumers[J]. Zoonoses Public Health, 2020, 67(7): 805-813. |
| [4] | Deng HF, Swart A,Bona?i? Marinovi? AA, et al. The effect of salting on Toxoplasma gondii viability evaluated and implemented in a quantitative risk assessment of meat-borne human infection[J]. Int J Food Microbiol, 2020, 314: 108380. |
| [5] | Murillo-Léon M, Bastidas-Quintero AM, Steinfeldt T. Decoding Toxoplasma gondii virulence: The mechanisms of IRG protein inactivation[J]. Trends Parasitol, 2024, 40(9): 805-819. |
| [6] | Zhao XY, Ewald SE. The molecular biology and immune control of chronic Toxoplasma gondii infection[J]. J Clin Invest, 2020, 130(7): 3370-3380. |
| [7] | Pittman KJ, Aliota MT, Knoll LJ. Dual transcriptional profiling of mice and Toxoplasma gondii during acute and chronic infection[J]. BMC Genomics, 2014, 15(1): 806. |
| [8] | Diniz DG, Guerreiro LCF, et al. Contrasting disease progression, microglia reactivity, tolerance, and resistance to Toxoplasma gondii infection in two mouse strains[J]. Biomedicines, 2024, 12(7): 1420. |
| [9] | Tyumentseva M, Tyumentsev A, Akimkin V. CRISPR/Cas9 landscape: Current state and future perspectives[J]. Int J Mol Sci, 2023, 24(22): 16077. |
| [10] | 王聪, 程维晟, 刘芳, 等. 基于CRISPR/Cas9技术的弓形虫rop16Ⅰ/Ⅲ缺陷虫株的构建及毒力鉴定[J]. 中国人兽共患病学报, 2017, 33(1): 22-26, 31. |
| Wang C, Cheng WS, Liu F, et al. CRISPR/Cas9-based construction of rop16Ⅰ/Ⅲ deficient strain of Toxoplasma gondii and its virulence identification[J]. Chin J Zoonoses, 2017, 33(1): 22-26, 31. (in Chinese) | |
| [11] | 吴燕, 张欣, 李瑾, 等. 基于CRISPR/Cas9技术的弓形虫病疫苗研究进展[J]. 中国血吸虫病防治杂志, 2024, 36(5): 542-547. |
| Wu Y, Zhang X, Li J, et al. Progress of researches on toxoplasmosis vaccines based on the CRISPR/Cas9 technology[J]. Chin J Schisto Control, 2024, 36(5): 542-547. (in Chinese) | |
| [12] | 贾永根, 闫爱霞, 黄敏君, 等. 基于CRISPR/Cas9技术对刚地弓形虫假定蛋白TGGT1_310420的研究[J]. 中国寄生虫学与寄生虫病杂志, 2019, 37(2): 150-154, 160. |
| Jia YG, Yan AX, Huang MJ, et al. CRISPR/Cas9-based localization and functional analysis of Toxoplasma gondii putative protein TGGT1_310420[J]. Chin J Parasitol Parasit Dis, 2019, 37(2): 150-154, 160. (in Chinese) | |
| [13] | Seo HH, Han HW, Lee SE, et al. Modelling Toxoplasma gondii infection in human cerebral organoids[J]. Emerg Microbes Infect, 2020, 9(1): 1943-1954. |
| [14] | Wu MM, Cudjoe O, Shen JL, et al. The host autophagy during Toxoplasma infection[J]. Front Microbiol, 2020, 11: 589604. |
| [15] | Licon MH, Giuliano CJ, Chan AW, et al. A positive feedback loop controls Toxoplasma chronic differentiation[J]. Nat Microbiol, 2023, 8(5): 889-904. |
| [16] | Wang FR, Holmes MJ, Hong HJ, et al. Translation initiation factor eIF1.2 promotes Toxoplasma stage conversion by regulating levels of key differentiation factors[J]. Nat Commun, 2024, 15(1): 4385. |
| [17] | Waldman BS, Schwarz D, WadsworthMH 2nd, et al. Identification of a master regulator of differentiation in Toxoplasma[J]. Cell, 2020, 180(2): 359-372. e16. |
| [18] | Walrad P, Paterou A, Acosta-Serrano A, et al. Differential trypanosome surface coat regulation by a CCCH protein that co-associates with procyclin mRNA cis-elements[J]. PLoS Pathog, 2009, 5(2): e1000317. |
| [19] | Wang JL, Li TT, Elsheikha HM, et al. The protein phosphatase 2A holoenzyme is a key regulator of starch metabolism and bradyzoite differentiation in Toxoplasma gondii[J]. Nat Commun, 2022, 13(1): 7560. |
| [20] | Gupta D, Bhattacharjee O, Mandal D, et al. CRISPR-Cas9 system: A new-fangled dawn in gene editing[J]. Life Sci, 2019, 232: 116636. |
/
| 〈 |
|
〉 |